孟怡然;段春梅;邓媛;顾悦;孙荣基;苏杭;杜江;赵敏;

• 1:云南省药物依赖防治研究所
• 2:上海交通大学医学院附属精神卫生中心

摘要(Abstract)：

目的:探讨合成大麻成瘾者心理治疗方面的操作方法、经验和效果。方法:以1例青少年合成大麻成瘾患者为对象,运用Matrix门诊强化干预方法中的早期康复技能训练、预防复吸和家庭治疗方法,开展为期8周共16次心理治疗。根据患者尿液毒品检测、自我报告和家人观察,评估治疗后保持戒断的康复时长;根据Cogstate计算机认知评估测评工具,评估治疗前后认知功能的变化。结果:治疗结束后的第3个月、第8个月持续随访,患者未复吸,保持戒断状况良好。治疗后患者完成Cogstate言语学习记忆、空间问题解决和错误监管能力、工作记忆和空间工作记忆任务的准确度提升,错误数下降。结论:在合成大麻成瘾者的心理治疗中运用Matrix门诊强化干预方法,可改善患者认知功能,保持戒断,促进康复。

关键词(KeyWords)： 合成大麻成瘾;青少年;心理治疗;Matrix干预模式

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 孟怡然;段春梅;邓媛;顾悦;孙荣基;苏杭;杜江;赵敏;

Email:

DOI:

参考文献(References)：

• [1] WinstockAR,Barratt MJ.Synthetic cannabis:a comparison of patterns of use and effect profile with natural cannabis in a large global sample[J].Drug Alcohol Depend,2013,131(1-2):106-111.
• [2] MathewsEM,JeffriesE,HsiehC,et al.Synthetic cannabinoid use among college students[J].Addict Behav,2019,93(6):219-224.
• [3] Obert J,McCann M,Rawson RA.Development and dissemination of the Matrix model of intensive outpatient treatment.Firstversion[M].//el-Guebaly N,Carra G,GalanterM,eds.Textbook of Addiction Treatment:International Perspectives.Milano:Springer,2015:961-971
• [4] 孟怡然,张丽琼.在我国强制隔离戒毒所运用美国Matrix干预模式的体会与思考[J].中国药物滥用防治杂志,2018,24(5):260-262.
• [5] 杜江,钟娜,Vladimir Poznyak,等.ICD-11精神与行为障碍(草案)关于物质使用障碍与成瘾行为障碍诊断标准的进展[J].中华精神科杂志,2018,(2):90-92.doi:10.3760/cma.j.issn.1006-7884.2018.02.003
• [6] World Health Organization.International Classification of Diseases,11th Revision (ICD-11)[EB /OL]World Health Organization.(2019-4).[2020-4-29].https://icd.who.int/browse11/l-m/en.
• [7] Hamilton M.The assessment of anxiety states by rating[J].PsycholPsychother Theory Res Pract,1959,32(1):50 -55.
• [8] Hamilton M.Development of a rating scale for primary depressive illness[J].Br J SocClin Psychol,1967,6(4):278-296.
• [9] 钟娜,赵敏.计算机化认知测试CogState量表及其适用性[J].心理学通讯,2019,2(1):67-70.
• [10]U.S.Department of Health and Human Services(DHHS).Counselor' s treatment manual:Matrix intensive outpatient treatment for people with stimulant use disorders.[EB/OL].Rockville,MD:Substance Abuse andMental Health Services Administration(SAMHSA).(2013-10)[2020-4-29].https://store.samhsa.gov/product/Matrix-Intensive-Outpatient-Treatment-for-People-With-Stimulant-Use-Disorders-Counselor-s-Treatment-Manual/SMA13-4152
• [11]U.S.Department of Health and Human Services(DHHS).Matrix intensive outpatient treatment for people with stimulant use disorders:client' s handbook.[EB /OL]Rockville,MD:Substance Abuse andMental Health Services Administration(SAMHSA)(2015-10)[2020-4-29].https://store.samhsa.gov/product/Matrix-Intensive-Outpatient-Treatment-for-People-With-Stimulant-Use-Disorders-Client-s-Handbook/SMA15-4154
• [12]U.S.Department of Health and Human Services(DHHS).Matrix intensive outpatient treatment for people with stimulant use disorders:client' s treatment companion.[EB/OL] Rockville,MD:Substance Abuse andMental Health Services Administration(SAMHSA).(2014-7)[2020-4-29].https://store.samhsa.gov/product/Matrix-Intensive-Outpatient-Treatment-for-People-With-Stimulant-Use-Disorders-Client-s-Treatment-Companion/SMA14-4155
• [13]United Nations Office on Drugs and Crime (UNODC).World drug report 2019.[EB /OL]United Nations.(2019-6).[2020-4-29].https://wdr.unodc.org/wdr2019/prelaunch/WDR19_Booklet_5_CANNABIS_HALLUCINOGENS.pdf
• [14]Winstock A,Lynskey M,Borschmann R,et al.Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample[J].J Psychopharmacol,2015,29(6):698-703.
• [15]Davis C,Boddington D.Teenage cardiac arrest following abuse of synthetic cannabis[J].Heart Lung,2015,24(10):e162.doi:10.1016/j.hlc.2015.04.176
• [16]Bernson-Leung ME,Leung LY,Kumar S.Synthetic cannabis and acute ischemic stroke[J].J Stroke Cerebrovascul Dis,2014,23(5):1239-1241.
• [17]Sznitman SR,Lianna PT,Maisar S,et al.Cannabis and synthetic cannabinoid exposure reported to the Israel poison information center:examining differences in exposures to medical and recreational compounds[J].IntJDrug Policy,2020,77102711:doi:org/10.1016/j.drugpo.2020.102711
• [18]Lee DC,Schlienz NJ,Peters EN,et al.Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder[J].Drug AlcoholDepend,2019,194:500-517.doi:10.1016/j.drugalcdep.2018.10.020.
• [19]Elevins CE,Eanes KE,Stephens RS,et al.A preliminary evaluation of synthetic cannabinoid use among adolescent cannabis users:characteristics and treatment outcomes[J].Addict Behav,2016,63:114-119.doi:10.1016/j.addbeh.2016.07.005.
• [20]陈慧,曾红.青少年成瘾物质使用的影响因素分析[J].中国药物依赖性杂志,2014,23(6):31-36.
• [21]Cengel HY,Bozkurt M,Evren C,et al.Evaluation of cognitive functions in individuals with synthetic cannabinoid use disorder and comparison to individuals with cannabis use disorder[J].Psychiatry Res,2018,262(4):46-54.
• [22]Cohen K,Kapitány-F?vény M,Mama Y,et al.The effects of synthetic cannabinoids on executive function[J].Psychopharmacology,2017,234(7):1121-1134.
• [23]Cohen K,WwinarwinA.The effects of cannabinoids on executive functions:evidence from cannabis and synthetic cannabinoids-asystematicreview[J].Brain Sci,2018,8(3):40.doi:10.3390/brainsci8030040.
• [24]LivnyA,Cohen K,Tik N,et al.The effects of synthetic cannabinoids (SCs) on brain structure and function[J].EurNeuropsychopharmacol,2018,28(9):1047-1057.